Comparison of Ramosetron with Palonosetron for Prevention of Postoperative Nausea and Vomiting in Patients Receiving Opioid-Based Intravenous Patient-Controlled Analgesia after Gynecological Laparoscopy

• Published in: BioMed research international Vol. 2017; no. 2017; pp. 1 - 6
• Main Authors: Jung, Yong Hun, Baek, Chong Wha, Kang, Hyun, Choi, Geun Joo, Ahn, Eun Jin, Woo, Young Cheol
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; John Wiley & Sons, Inc
• Subjects: Adult; Aged; Analgesia; Analgesia, Patient-Controlled - adverse effects; Analgesics; Analgesics, Opioid - adverse effects; Anesthesia; Anesthesiology; Antagonists (Biochemistry); Antiemetics; Benzimidazoles - administration & dosage; Comparative analysis; Complications; Complications and side effects; Confounding (Statistics); Dosage and administration; Drug dosages; Electronic Health Records; Female; Fentanyl; Gynecologic Surgical Procedures - adverse effects; Gynecology; Hospitals; Humans; Isoquinolines - administration & dosage; Laparoscopic surgery; Laparoscopy; Laparoscopy - adverse effects; Medicine; Middle Aged; Narcotics; Nausea; Pain; Pain, Postoperative - drug therapy; Pain, Postoperative - physiopathology; Patient outcomes; Patient satisfaction; Postoperative Nausea and Vomiting - chemically induced; Postoperative Nausea and Vomiting - drug therapy; Postoperative Nausea and Vomiting - physiopathology; Prevention; Quinuclidines - administration & dosage; Surgery; Vomiting; South Korea
• ISSN: 2314-6133; 2314-6141; 2314-6141
• DOI: 10.1155/2017/9341738

We aimed to compare the effects of ramosetron and palonosetron in the prevention of postoperative nausea and vomiting (PONV) in patients that received opioid-based intravenous patient-controlled analgesia (IV-PCA) after gynecological laparoscopy. We reviewed the electronic medical records of 755 adults. Patients were classified into two groups, ramosetron (group R, n=589) versus palonosetron (group P, n=166). Based on their confounding factors, 152 subjects in each group were selected after the implementation of propensity score matching. The overall incidence of PONV at postoperative day (POD) 0 was lower in group R compared to group P (26.9% versus 36.8%; P=0.043). The severity of nausea was lower in group R than in group P on postoperative day (POD) 0 (P=0.012). Also, the complete responder proportion of patients was significantly higher in group R compared to that in group P on POD 0 (P=0.043). In conclusion, ramosetron showed a greater efficacy in the prevention of postoperative nausea at POD 0 compared to palonosetron in patients after gynecological laparoscopy.